Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Ohio Urologists Hit by Overseas Hackers

November 25th 2016

If any doubts remained that oncology practices were not going to be specific targets in the hacking of medical data, a breach at Central Ohio Urology Group has set the record straight.

FDA Issues Complete Response Letter for Apaziquone in Bladder Cancer

November 19th 2016

The FDA has issued a complete response letter to Spectrum Pharmaceuticals informing the company that its new drug application for apaziquone in bladder cancer would not be approved.

Immunotherapy Becomes Mainstay in Bladder Cancer Care

November 19th 2016

The PD-1/PD-L1 inhibitors moving through the pipeline in bladder cancer will have a lasting impact on the armamentarium in the field, explains Jonathan E. Rosenberg, MD.

Dr. Iyer on Advice for Physicians Using Immunotherapy in Bladder Cancer

November 18th 2016

Gopa Iyer, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses significant points for community oncologists to be aware of when treating patients with bladder cancer with immunotherapy agents.

New Options Emerge in Frontline, Adjuvant RCC Care

November 17th 2016

Therapeutic options for patients with renal cell carcinoma have increased rapidly in the past decade, yet the field is still poised to expand significantly in the coming years, said Robert S. Alter, MD.

First-Line Cabozantinib Superior to Sunitinib in mRCC

November 17th 2016

Cabozantinib reduced the risk of progression or death by 34% versus sunitinib as a first-line treatment for patients with metastatic renal cell carcinoma, according to results from the phase II CABOSUN trial.

Kantoff Highlights Continued Role for Docetaxel in Metastatic Prostate Cancer

November 16th 2016

While immunotherapy continues to make headway in various malignancies, the chemotherapy docetaxel maintains a key role in the treatment of patients with metastatic prostate cancer.

Nivolumab/Ipilimumab Combo Highly Effective for Pretreated Metastatic Urothelial Carcinoma

November 14th 2016

The combination of nivolumab and ipilimumab led to a high response rate and improved overall survival versus historical controls for patients with pretreated metastatic urothelial carcinoma.

Pembrolizumab OS Benefit Sets New Benchmark in Second-Line Bladder Cancer

November 13th 2016

Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.

Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer

November 13th 2016

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.

Dr. Touijer on Surgical Options for Patients with RCC

November 9th 2016

Karim A. Touijer, MD, MPH, surgeon, Memorial Sloan Kettering Cancer Center, discusses the considering factors for surgical options for patients with renal cell carcinoma (RCC).

RECORD-3 Molecular Analysis Characterizes Poor-Risk Patients With mRCC

November 8th 2016

To best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.

Dr. Hsieh on Patient Characterization From RECORD-3 Study in Metastatic RCC

November 8th 2016

James J. Hsieh, MD, medical oncologist, physician-scientist, Memorial Sloan Kettering Cancer Center, discusses overall survival results in the RECORD-3 study based on 3 distinct clear cell metastatic renal cell carcinoma molecular subgroups.

Dr. Uzzo on Potential of Adjuvant Therapy in Patients With RCC

November 8th 2016

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).

Potential for Neoadjuvant Immunotherapy in Bladder Cancer Is Wide Open, Expert Says

November 7th 2016

With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.

Nimble, Larger Practices Can Thrive Under New Healthcare Delivery Models

November 7th 2016

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

Systemic Immunotherapy Use Expanding Rapidly in Bladder Cancer

November 6th 2016

Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.

Lenvatinib Regimen Setting Pace for Emerging Combos in Kidney Cancer

November 6th 2016

The dual inhibitor combination of lenvatinib and everolimus is becoming an essential second-line treatment option in advanced renal cell carcinoma, and research to move the regimen into frontline settings is underway.

Novel Therapies Offer Hope for BCG-Unresponsive Bladder Cancer

November 5th 2016

A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.

RCC Experts Consider Immunotherapy Integral to Optimizing Adjuvant Care

November 5th 2016

Looking ahead to 2020, most participants on an expert panel projected that immunotherapy will be critical to optimizing outcomes in the adjuvant setting for patients with renal cell carcinoma.